Cargando…
Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer
BACKGROUND: Data supporting high tumor mutational burden (TMB-H) as a lone biomarker for an immune-responsive tumor microenvironment (TME) in metastatic breast cancer (MBC) are weak, yet tumor agnostic approval in TMB-H advanced tumors provides immune checkpoint inhibition (ICI) as a clinical option...
Autores principales: | Sammons, Sarah, Elliott, Andrew, Barroso-Sousa, Romualdo, Chumsri, Saranya, Tan, Antoinette R., Sledge, George W., Tolaney, Sara M., Torres, Evanthia T. Roussos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457522/ https://www.ncbi.nlm.nih.gov/pubmed/37637072 http://dx.doi.org/10.3389/fonc.2023.1235902 |
Ejemplares similares
-
Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2023) -
Tumor mutational burden as a predictor of immunotherapy response in breast cancer
por: O’Meara, Tess A., et al.
Publicado: (2021) -
Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2021) -
Evidence to date: talazoparib in the treatment of breast cancer
por: Exman, Pedro, et al.
Publicado: (2019) -
Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide
por: Mirando, Adam C., et al.
Publicado: (2020)